ChiCTR-OIC-17010625
结束
/
/
/
2017-02-02
/
/
退化性膝關節炎
先導計劃 - 研究富血小板血漿注射治療退化性膝關節炎
先導計劃 - 研究富血小板血漿注射治療退化性膝關節炎
研究富血小板血漿注射治療退化性膝關節炎
单臂
Ⅱ期
NA
/
NA
/
12
/
1990-01-01
1990-01-01
/
1) Aged 45 to 75 years old; 2) Self-reported symptoms consistent with KOA per American College of Rheumatology guidelines; 3) Have experienced moderate to severe knee pain for at least 3 months, defined as a score of 3 or more (0-6 ordinal response scale) on the question "What is the average level of your left/right knee pain?" 4) Failed 6 months of usual care; 5) Clinical evidence of KOA according to the American College of Rheumatology guidelines; 6) Radiographic evidence of KOA with Kellgren Lawerance (KL).；
请登录查看1) Pregnancy; 2) On anticoagulation, immunosuppressive or daily opioid therapy; 3) History of collagen tissue or other autoimmune disorders; 4) Hematological diseases; 5) Severe cardiovascular diseases; 6) Prior or planned total knee replacement of the affected knee; 7) Allergy or intolerance to acetaminophen or xylocaine; 8) Body mass index (BMI) ≥ 35 kg/m2; 9) Co-morbidity severe enough to prevent reliable or safe study participation; 10) Subjects who cannot read or write in the Chinese Consent form; 11) Interim knee joint infectious arthritis or trauma; 12) Hemoglobin level < 11g/dL; 13) Platelet concentration < 150,000/mm3; 14) Clinical examination suggesting that the patient is not appropriate due to comorbid knee or other conditions.；
请登录查看The Jockey Club School of Public Health and Primary Care, The Chinese University of Hong Kong
/
The Jockey Club School of Public Health and Primary Care, The Chinese University of Hong Kong的其他临床试验
Division of Family Medicine and Primary Health Care, The Jockey Club School of Public Health and Primary Care, The Chinese University of Hong Kong的其他临床试验
最新临床资讯
-
大鹏制药临床III期成功
新药说2026-08-13
-
新一代 EGFR-TKI 首个全球 III 期成功
丁香园 Insight 数据库2026-08-13
-
体外诊断原料网2026-08-13
-
佰傲谷BioValley2026-08-13
-
久有基金2026-08-13
-
重庆宸安生物2026-08-13
-
UmabsDB2026-08-13
-
希格生科2026-08-13
-
bioSeedin柏思荟2026-08-13
-
智飞智讯2026-08-13
全球药物研发中心
全球研发数据与行业前沿情报
研发动态
相关报告
政策法规
-
2026-08-13
-
2026-08-13
-
2026-08-13
-
摩熵咨询 20 8
-
摩熵咨询 34 27
-
摩熵咨询 20 5
-
颁布机构：四川省经济和信息化厅、中共四川省委军民融合发展委员会办公室、四川省教育厅、四川省科学技术厅、四川省人力资源和社会保障厅、四川省卫生健康委员会、四川省医疗保障局、四川省中医药管理局、四川省药品监督管理局 2026-08-04
-
颁布机构：国家医保局 2026-07-31
-
颁布机构：国家药品审评中心（CDE） 2026-07-24
医药市场洞察中心
医药市场销售数据分析 · 智能洞察 · 竞争格局监测
-
医药市场销售数据分析 · 医院、实体药店、网上药店
-
市场竞争格局分析(靶点、药品类型、ATC大类)
市场动态
市场报告
政策法规
-
2026-08-13
-
2026-08-13
-
2026-08-13
-
摩熵咨询 35 36
-
摩熵咨询 28 38
-
摩熵咨询 34 18
-
颁布机构：国家市场监督管理总局 2026-08-10
-
颁布机构：国家市场监督管理总局 2026-05-29
-
颁布机构：国家市场监督管理总局 2026-05-29